OncoMatch/Clinical Trials/NCT07070440
DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
Is NCT07070440 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including DZD6008 and Pemetrexed for non small cell lung cancer.
Treatment: DZD6008 · Pemetrexed · Carboplatin · Docetaxel — This study is designed to evaluate safety and antitumor activity of DZD6008 combination therapy in patients with advanced Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Biomarker criteria
Required: EGFR sensitizing mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: EGFR tyrosine kinase inhibitor
Failure of prior 3 generations EGFR TKI.
Cannot have received: immunotherapy
Exception: within 4 weeks before the first study drug administration
Received immunotherapy or other antibody treatments (including EGFR-targeted antibodies, bispecific antibodies or antibody-drug conjugates, etc.) within 4 weeks before the first study drug administration.
Cannot have received: cytotoxic chemotherapy
Exception: within 14 days before the first study drug administration
Received any cytotoxic chemotherapy, study drugs or other anti-cancer drugs (excluding macromolecule drugs) within 14 days before the first study drug administration.
Cannot have received: radiation therapy
Exception: limited-range radiotherapy to relieve the disease within 7 days before the first study drug administration, or received more than 30% of the bone marrow radiotherapy or received wide-range radiotherapy within 28 days before the first medication
Received limited-range radiotherapy to relieve the disease within 7 days before the first study drug administration, or received more than 30% of the bone marrow radiotherapy or received wide-range radiotherapy within 28 days before the first medication.
Cannot have received: major invasive surgery
Exception: within 4 weeks before the first study drug administration or is planned during treatment
Major invasive surgery has been performed within 4 weeks before the first study drug administration or is planned during treatment.
Lab requirements
Blood counts
Sufficient bone marrow or other organ reserve before first dosing.
Cardiac function
QT interval (QTc) >470 msec after calibration of 12-lead ECG at rest during the screening period. Any serious abnormalities of heart rate, conduction or pattern shown on the ECG at rest, such as complete left bundle branch block, third degree heart block, second degree heart block, PR interval >250 msec. Any disease or condition that can cause QTcF prolongation or arrhythmia, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or family members with a history of sudden death under the age of 40. Severe cardiovascular diseases such as myocardial infarction, unstable angina or congestive heart failure, cerebrovascular accident (such as history of stroke or intracranial hemorrhage) within 6 months before the first dose. History of deep vein thrombosis or pulmonary embolism within 4 weeks before the first dose (excluding non-obstructive catheter-related thrombosis).
Sufficient bone marrow or other organ reserve before first dosing. See exclusion criteria for cardiac details.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify